|
|
非小细胞肺癌组织中RBM3的表达及其与患者预后的相关性研究
|
Abstract:
目的：探讨RBM3 (RNA结合基序蛋白3，RNA binding motif protein 3)在非小细胞肺癌(Non-Small Cell Lung Cancer, NSCLC)组织中的表达情况及其与患者临床病理学参数和预后的关系。方法：收集2014年8月1日至2015年8月1日在青岛市市立医院东院区胸外科行肺癌根治术的135例NSCLC患者，通过免疫组化染色方法检测RBM3的表达情况，通过卡方检验分析其与患者临床病理学参数的相关性，采用Kaplan-Meier法、log-rank检验法和Cox比例风险模型统计RBM3表达与患者OS (总生存期)及PFS (无进展生存期)的关系。结果：RBM3的表达与肿瘤组织分化程度(P = 0.015)、N分期(P = 0.005)、T分期(P = 0.032)、LVD (淋巴管密度，以D2-40进行标记) (P = 0.039)及MVD (微血管密度，以CD34进行标记) (P = 0.035)明显相关，差异具有统计学意义(P < 0.05)；单因素Cox回归分析表明：RBM3的表达、肿瘤组织分化程度、LVD、MVD、T分期、N分期是影响非小细胞肺癌的OS的因素(P < 0.05)；RBM3的表达、肿瘤组织分化程度、LVD、MVD、N分期是影响非小细胞肺癌的PFS的因素(P < 0.05)；Cox比例风险模型多因素分析表明，RBM3、N分期、T分期及LVD、MVD是影响NSCLC患者OS及PFS的独立危险因素(P < 0.05)。生存分析提示低表达RBM3患者的OS、PFS明显长于高表达RBM3的患者。结论：RBM3、N分期、T分期、LVD、MVD是非小细胞肺癌独立的预后因素。RBM3可能成为非小细胞肺癌总体生存率的预后标志物，并可能成为非小细胞肺癌治疗的潜在靶点，具有广阔的治疗前景。
Objective: To investigate the expression of RBM3 (RNA binding motif protein 3) in non-small cell lung cancer (NSCLC) tissues and its relationship with clinical pathological parameters and prognosis of patients. Methods: A total of 135 patients with NSCLC who underwent radical resection of lung cancer in Department of Chest Surgery, Qingdao Municipal Hospital East Campus from August 1, 2014 to August 1, 2015 were collected. The expression of RBM3 was detected by immunohisto-chemistry, and its correlation with clinical pathological parameters was analyzed by Chi square test. The Kaplan-Meier method, log-rank test and Cox proportional risk model were used to calculate the relationship between RBM3 expression and OS (overall survival) and PFS (progression-free survival) of the patients. Results: The expression of RBM3 was significantly correlated with the degree of dif-ferentiation (P = 0.015), N-stage (P = 0.005), T-stage (P = 0.032), LVD (lymphatic vessel density, la-beled with D2-40) (P = 0.039) and MVD (microvessel density, labeled with CD34) (P = 0.035) (both P < 0.05). Univariate Cox regression analysis showed that the expression of RBM3, tumor tissue dif-ferentiation, LVD, MVD, T-stage, and N-stage were the factors affecting OS in NSCLC (P < 0.05). The expression of RBM3, the differentiation degree of tumor tissue, LVD, MVD, and N-stage were the fac-tors that affected the PFS of NSCLC (P < 0.05). Multivariate analysis using Cox proportional hazards model showed that RBM3, N-stage, T-stage, LVD and MVD were the independent risk factors for OS and PFS in patients with NSCLC (P < 0.05). Survival analysis indicated that the OS and PFS of pa-tients with low expression of RBM3 were significantly longer than those of patients with high ex-pression of RBM3.
| [1] | De Angelis, R., Sant, M., Coleman, M.P., et al. (2014) Cancer Survival in Europe 1999-2007 by Country and Age: Re-sults of EUROCARE-5—A Population-Based Study. The Lancet Oncology, 15, 23-34.
https://doi.org/10.1016/S1470-2045(13)70546-1 |
| [2] | Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660 |
| [3] | Allemani, C., Matsuda, T., Di Carlo, V., et al. (2018) Global Surveillance of Trends in Cancer Survival 2000-14 (CONCORD-3): Analysis of Individual Records for 37513025 Patients Diag-nosed with One of 18 Cancers from 322 Population-Based Registries in 71 Countries. The Lancet (London, England), 391, 1023-1075.
https://doi.org/10.1016/S0140-6736(17)33326-3 |
| [4] | Zeng, H., Chen, W., Zheng, R., et al. (2018) Changing Can-cer Survival in China during 2003-15: A Pooled Analysis of 17 Population-Based Cancer Registries. The Lancet Global Health, 6, e555-e567.
https://doi.org/10.1016/S2214-109X(18)30127-X |
| [5] | Derry, J.M., Kerns, J.A. and Francke, U. (1995) RBM3, a Novel Human Gene in Xp11.23 with a Putative RNA-Binding Domain. Human Molecular Genetics, 4, 2307-2311. https://doi.org/10.1093/hmg/4.12.2307 |
| [6] | Zeng, Y., Wodzenski, D., Gao, D., et al. (2013) Stress-Response Pro-tein RBM3 Attenuates the Stem-Like Properties of Prostate Cancer Cells by Interfering with CD44 Variant Splicing. Cancer Research, 73, 4123-4133.
https://doi.org/10.1158/0008-5472.CAN-12-1343 |
| [7] | Baghdoyan, S., Dubreuil, P., Eberlé, F. and Gomez, S. (2000) Capture of Cytokine-Responsive Genes (NACA and RBM3) Using a Gene Trap Approach. Blood, 95, 3750-3757.
https://doi.org/10.1182/blood.V95.12.3750.012a24_3750_3757 |
| [8] | Venugopal, A., Subramaniam, D., Balmaceda, J., et al. (2016) RNA Binding Protein RBM3 Increases β-Catenin Signaling to Increase Stem Cell Characteristics in Col-orectal Cancer Cells. Molecular Carcinogenesis, 55, 1503-1516.
https://doi.org/10.1002/mc.22404 |
| [9] | Sureban, S.M., Ramalingam, S., Natarajan, G., et al. (2008) Translation Regulatory Factor RBM3 Is a Proto-Oncogene That Prevents Mitotic Catastrophe. Oncogene, 27, 4544-4556. https://doi.org/10.1038/onc.2008.97 |
| [10] | Ehlén, A., Brennan, D.J., Nodin, B., et al. (2010) Expression of the RNA-Binding Protein RBM3 Is Associated with a Favourable Prognosis and Cisplatin Sensitivity in Epithelial Ovarian Cancer. Journal of Translational Medicine, 8, 78.
https://doi.org/10.1186/1479-5876-8-78 |
| [11] | Boman, K., Segersten, U., Ahlgren, G., et al. (2013) Decreased Ex-pression of RNA-Binding Motif Protein 3 Correlates with Tumour Progression and Poor Prognosis in Urothelial Bladder Cancer. BMC Urology, 13, 17.
https://doi.org/10.1186/1471-2490-13-17 |
| [12] | Jonsson, L., Bergman, J., Nodin, B., et al. (2011) Low RBM3 Pro-tein Expression Correlates with Tumour Progression and Poor Prognosis in Malignant Melanoma: An Analysis of 215 Cases from the Malm？ Diet and Cancer Study. Journal of Translational Medicine, 9, 114. https://doi.org/10.1186/1479-5876-9-114 |
| [13] | Jonsson, L., Hedner, C., Gaber, A., et al. (2014) High Expression of RNA-Binding Motif Protein 3 in Esophageal and Gastric Adenocarcinoma Correlates with Intestinal Metapla-sia-Associated Tumours and Independently Predicts a Reduced Risk of Recurrence and Death. Biomarker Research, 2, 11. https://doi.org/10.1186/2050-7771-2-11 |
| [14] | Molina, J.R., Yang, P., Cassivi, S.D., Schild, S. and Adjei, A.A. (2008) Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic Proceed-ings, 83, 584-594.
https://doi.org/10.1016/S0025-6196(11)60735-0 |
| [15] | Tas, F., Ciftci, R., Kilic, L. and Karabulut, S. (2013) Age Is a Prognostic Factor Affecting Survival in Lung Cancer Patients. Oncology Letters, 6, 1507-1513. https://doi.org/10.3892/ol.2013.1566 |
| [16] | 王瑞, 赵佳, 张龙. 肺腺癌患者肺组织中RBM3 mRNA表达及意义[J]. 临床肺科杂志, 2019, 24(12): 2236-2240. |
| [17] | Zhou, R.B., Lu, X.L., Zhang, C.Y. and Yin, D.C. (2017) RNA Binding Motif Protein 3: A Potential Biomarker in Cancer and Therapeutic Target in Neuroprotection. Oncotarget, 8, 22235-22250.
https://doi.org/10.18632/oncotarget.14755 |
| [18] | J？gi, A., Brennan, D., Rydén, L., et al. (2009) Nuclear Expression of the RNA-Binding Protein RBM3 Is Associated with an Improved Clinical Outcome in Breast Cancer. Modern Pa-thology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 22, 1564-1574. https://doi.org/10.1038/modpathol.2009.124 |
| [19] | Ehlén, ？., Nodin, B., Rexhepaj, E., et al. (2011) RBM3-Regulated Genes Promote DNA Integrity and Affect Clinical Outcome in Epithelial Ovarian Cancer. Translation-al Oncology, 4, 212-221. https://doi.org/10.1593/tlo.11106 |
| [20] | O’Connell, R.M., Rao, D.S., Chaudhuri, A.A. and Baltimore, D. (2010) Physiological and Pathological Roles for microRNAs in the Immune System. Nature Reviews Im-munology, 10, 111-122. https://doi.org/10.1038/nri2708 |
| [21] | Jonsson, L., Gaber, A., Ulmert, D., et al. (2011) High RBM3 Expression in Prostate Cancer Independently Predicts a Reduced Risk of Biochemical Recurrence and Disease Progression. Diagnostic Pathology, 6, 91.
https://doi.org/10.1186/1746-1596-6-91 |
| [22] | Yang, G., Fu, H., Zhang, J., et al. (2010) RNA-Binding Protein Quaking, a Critical Regulator of Colon Epithelial Differentiation and a Suppressor of Colon Cancer. Gastroenterology, 138, 231-240.e231-235.
https://doi.org/10.1053/j.gastro.2009.08.001 |
| [23] | Schneider, J., Gómez-Esquer, F., Díaz-Gil, G., Torrejón, R. and Pollán, M. (2011) mRNA Expression of the Putative Antimetastatic Gene BRMS1 and of Apoptosis-Related Genes in Breast Cancer. Cancer Genomics & Proteomics, 8, 195-197. |
| [24] | Ye, F., Jin, P., Cai, X., Cai, P. and Cai, H. (2017) High RNA-Binding Motif Protein 3 (RBM3) Expression Is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 23, 6033-6041.
https://doi.org/10.12659/MSM.905314 |
| [25] | 曾丹, 华金仁, 安云婷. RBM3在卵巢上皮性癌中的表达及临床意义[J]. 当代医学, 2016, 22(31): 14-15. |
| [26] | Zhang, H.T., Zhang, Z.W., Xue, J.H., Kong, H.B., Liu, A.J., Li, S.C., et al. (2013) Differential Expression of the RNA-Binding Motif Protein 3 in Human Astrocytoma. Chinese Medical Journal, 126, 1948-1952. |
| [27] | Ma, R., Zhao, L.N., Yang, H., et al. (2018) RNA Binding Motif Protein 3 (RBM3) Drives Radi-oresistance in Nasopharyngeal Carcinoma by Reducing Apoptosis via the PI3K/AKT/Bcl-2 Signaling Pathway. American Journal of Translational Research, 10, 4130-4140. |
| [28] | 郭俊杰, 李锁严, 董丽艳, 于伟杰, 刘翠萍, 韩明玥. 浸润性乳腺癌组织中RNA结合基序蛋白3的表达水平及意义[J]. 癌症进展, 2019, 17(12): 1449-1452. |
| [29] | Grupp, K., Hofmann, B., Kutup, A., et al. (2018) Reduced RBM3 Expression Is Associated with Aggressive Tumor Features in Esophageal Cancer but Not Significantly Linked to Patient Outcome. BMC Cancer, 18, 1106.
https://doi.org/10.1186/s12885-018-5032-z |
